_safety-and-efficacy-of-escalating-doses-of-the-hu5f9-g4-with-rituximab-in-patients-with-r-r-dlbcl-and-indolent-lymphoma.jpg "Safety and efficacy of escalating doses of the hu5f9-g4 with rituximab in patients with R R DLBCL and indolent lymphoma from car t study results Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 3 min 26 sec
✓ Published: 18-Jun-2019
✓ Published: 18-Jun-2019
Description:
Dr Mark Roschewski speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting on the phase IB/2 results of a study evaluating the safety and efficacy of escalating doses of the first-in-class anti-cd47 antibody hu5f9-g4 with rituximab in patients with R/R DLBCL and indolent lymphoma.nnHe explains that the study enrolled patients who were ineligible for CAR-T therapy as they would be considered as having very limited treatment options.nnDr Roschewski reports that the esca
Dr Mark Roschewski speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting on the phase IB/2 results of a study evaluating the safety and efficacy of escalating doses of the first-in-class anti-cd47 antibody hu5f9-g4 with rituximab in patients with R/R DLBCL and indolent lymphoma.nnHe explains that the study enrolled patients who were ineligible for CAR-T therapy as they would be considered as having very limited treatment options.nnDr Roschewski reports that the esca
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_kdigo-2024-anca-vasculitis-guideline-reading-between-the-lines.webp "KDIGO")
_t-for-tube.webp "T for TUBEnnThis project presents the results of our encounter with the turnstile of the Paris metro, from its discovery to the study of its form and function. In its actual use, the turnstile is an invisible object although we come into contact with it each time we take the metro. Over time, it also generates behaviors beyond its initial function. It is soon fated to disappear, to be replaced by new control devices. This has inspired us to tell its story while giving it a new life and a new fun")
_results-of-the-transcend-study-of-car-t-cell-product-jcar017-in-patients-with-r-r-aggressive-b-nhl.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
⏲ 6 minutes 24 seconds 👁 190
_sattva-s-neelapu-md-encouraging-results-for-car-t-cells-in-refractory-dlbcl.webp "American Society of Hematology")
⏲ 6 minutes 21 seconds 👁 697
_immunological-approaches-cars-to-armored-cars-t-cell-treatment-of-cancer.webp "HMP Education")
⏲ 24 minutes 31 seconds 👁 753
_car-t-cell-therapy-explained-animation-124-city-of-hope.webp "City of Hope")
_myeloma-bone-updated-results-on-anti-bcma-car-t-cell-therapy.webp "Kenneth C. Anderson, MD, of Dana-Farber Cancer Institute, and Noopur S. Raje, MD, of the Massachusetts General Hospital Cancer Center, discuss new findings from the first-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma.")
_preliminary-results-from-phase-i-study-of-cd123-car-t-therapy-in-pediatric-r-r-aml.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
⏲ 3 minutes 41 seconds 👁 107
_kdigo-2024-anca-vasculitis-guideline-reading-between-the-lines.jpg)
_t-for-tube.jpg)
_results-of-the-transcend-study-of-car-t-cell-product-jcar017-in-patients-with-r-r-aggressive-b-nhl.jpg)
_sattva-s-neelapu-md-encouraging-results-for-car-t-cells-in-refractory-dlbcl.jpg)
_immunological-approaches-cars-to-armored-cars-t-cell-treatment-of-cancer.jpg)
_car-t-cell-therapy-explained-animation-124-city-of-hope.jpg)
_myeloma-bone-updated-results-on-anti-bcma-car-t-cell-therapy.jpg)
_preliminary-results-from-phase-i-study-of-cd123-car-t-therapy-in-pediatric-r-r-aml.jpg)
![[+]](/images/menu.gif){kind=small}